IONIS HBVRx

Drug Profile

IONIS HBVRx

Alternative Names: 3228836; GSK3228836; IONIS-HBVRx; ISIS 505358; ISIS-GSK3Rx; ISIS-HBVRx

Latest Information Update: 10 Apr 2017

Price : $50

At a glance

  • Originator Isis Pharmaceuticals
  • Developer Ionis Pharmaceuticals
  • Class Antisense oligonucleotides; Antivirals
  • Mechanism of Action Viral protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hepatitis B

Most Recent Events

  • 22 Feb 2017 Phase-II clinical trials in Hepatitis B (Treatment-naive) (SC) in Hong Kong (Ionis pipeline, April 2017) (NCT02981602)
  • 18 Feb 2016 Ionis completes a phase I trial in Hepatitis B infection (In volunteers) in USA (Ionis pipeline, February 2016)
  • 22 Jan 2016 Ionis plans a phase II trial for Hepatitis B infection in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top